{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:16:54Z","timestamp":1791274614672,"version":"4.1.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Canadian Institutes of Health Research"},{"name":"Saskatchewan Regional Partnership Program"},{"name":"NIH NS066091"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1016\/j.neuropharm.2012.04.016","type":"journal-article","created":{"date-parts":[[2012,4,25]],"date-time":"2012-04-25T17:16:42Z","timestamp":1335374202000},"page":"362-367","source":"Crossref","is-referenced-by-count":27,"title":["Sumatriptan inhibition of N-type calcium channel mediated signaling in dural CGRP terminal fibres"],"prefix":"10.1016","volume":"63","author":[{"given":"Landon D.","family":"Baillie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew H.","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean J.","family":"Mulligan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2012.04.016_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pain.2005.03.008","article-title":"Where do triptans act in the treatment of migraine?","volume":"115","author":"Ahn","year":"2005","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2012.04.016_bib2","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/nrn3057","article-title":"Diencephalic and brainstem mechanisms in migraine","volume":"12","author":"Akerman","year":"2011","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2012.04.016_bib3","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.tips.2004.07.004","article-title":"Targeting Ca2+ channels to treat pain: T-type versus N-type","volume":"25","author":"Altier","year":"2004","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2012.04.016_bib4","doi-asserted-by":"crossref","first-page":"6363","DOI":"10.1523\/JNEUROSCI.0307-07.2007","article-title":"Differential role of N-type calcium channel splice isoforms in pain","volume":"27","author":"Altier","year":"2007","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2012.04.016_bib5","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.neuroscience.2010.10.032","article-title":"Role for voltage gated calcium channels in calcitonin gene-related peptide release in the rat trigeminovascular system","volume":"172","author":"Amrutkar","year":"2011","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2012.04.016_bib6","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jneumeth.2011.04.015","article-title":"Functional imaging within individual pain fibres ex\u00a0vivo with optical microscopy","volume":"198","author":"Baillie","year":"2011","journal-title":"J.\u00a0Neurosci. Methods"},{"key":"10.1016\/j.neuropharm.2012.04.016_bib7","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/ana.20193","article-title":"Activation of 5-HT(1B\/1D) receptor in the periaqueductal gray inhibits nociception","volume":"56","author":"Bartsch","year":"2004","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2012.04.016_bib8","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1590\/S0004-282X2009000300040","article-title":"Migraine in the triptan era: progresses achieved, lessons learned and future developments","volume":"67","author":"Bigal","year":"2009","journal-title":"Arq. Neuropsiquiatr."},{"key":"10.1016\/j.neuropharm.2012.04.016_bib9","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/nn1417","article-title":"Control of synaptic strength and timing by the release-site Ca2+ signal","volume":"8","author":"Bollmann","year":"2005","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2012.04.016_bib10","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/0028-3908(91)90165-8","article-title":"Dihydroergotamine and sumatriptan attenuate levels of CGRP in plasma in rat superior sagittal sinus during electrical stimulation of the trigeminal ganglion","volume":"30","author":"Buzzi","year":"1991","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2012.04.016_bib11","doi-asserted-by":"crossref","first-page":"497","DOI":"10.4161\/chan.4.6.12871","article-title":"G\u00a0protein modulation of CaV2 voltage-gated calcium channels","volume":"4","author":"Currie","year":"2010","journal-title":"Channels (Austin)"},{"key":"10.1016\/j.neuropharm.2012.04.016_bib12","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1113\/jphysiol.1967.sp008367","article-title":"Co-operative action a calcium ions in transmitter release at the neuromuscular junction","volume":"193","author":"Dodge","year":"1967","journal-title":"J.\u00a0Physiol."},{"key":"10.1016\/j.neuropharm.2012.04.016_bib13","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.1523\/JNEUROSCI.19-09-03423.1999","article-title":"Regulation of calcitonin gene-related peptide secretion by a serotonergic antimigraine drug","volume":"19","author":"Durham","year":"1999","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2012.04.016_bib14","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0163-7258(02)00173-0","article-title":"New insights into the molecular actions of serotonergic antimigraine drugs","volume":"94","author":"Durham","year":"2002","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2012.04.016_bib15","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1523\/JNEUROSCI.23-03-00807.2003","article-title":"Stimulation of the calcitonin gene-related peptide enhancer by mitogen-activated protein kinases and repression by an antimigraine drug in trigeminal ganglia neurons","volume":"23","author":"Durham","year":"2003","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2012.04.016_bib16","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2165\/11534920-000000000-00000","article-title":"Calcitonin gene-related peptide (CGRP) receptor antagonists in the treatment of migraine","volume":"24","author":"Durham","year":"2010","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neuropharm.2012.04.016_bib17","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1111\/j.1526-4610.2008.01215.x","article-title":"Inhibition of calcitonin gene-related peptide function: a promising strategy for treating migraine","volume":"48","author":"Durham","year":"2008","journal-title":"Headache"},{"key":"10.1016\/j.neuropharm.2012.04.016_bib18","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.nurt.2010.02.004","article-title":"CGRP receptor antagonism and migraine","volume":"7","author":"Edvinsson","year":"2010","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neuropharm.2012.04.016_bib19","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1517\/13543784.2010.490829","article-title":"Calcitonin gene-related peptide receptor antagonists for migraine","volume":"19","author":"Fischer","year":"2010","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.neuropharm.2012.04.016_bib20","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/ana.410330109","article-title":"The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats","volume":"33","author":"Goadsby","year":"1993","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2012.04.016_bib21","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/ana.410280213","article-title":"Vasoactive peptide release in the extracerebral circulation of humans during migraine headache","volume":"28","author":"Goadsby","year":"1990","journal-title":"Ann. Neurol."},{"issue":"Suppl. 1","key":"10.1016\/j.neuropharm.2012.04.016_bib22","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1111\/j.1526-4610.2006.00675.x","article-title":"New migraine and pain research","volume":"47","author":"Hargreaves","year":"2007","journal-title":"Headache"},{"key":"10.1016\/j.neuropharm.2012.04.016_bib23","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/j.1468-2982.2008.01635.x","article-title":"Serotonin type 1D receptors (5HTR) are differentially distributed in nerve fibres innervating craniofacial tissues","volume":"28","author":"Harriott","year":"2008","journal-title":"Cephalalgia"},{"key":"10.1016\/j.neuropharm.2012.04.016_bib24","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrneurol.2010.127","article-title":"CGRP and its receptors provide new insights into migraine pathophysiology","volume":"6","author":"Ho","year":"2010","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.neuropharm.2012.04.016_bib25","article-title":"New agents for acute treatment of migraine: CGRP receptor antagonists, iNOS inhibitors","author":"Hoffmann","year":"2011","journal-title":"Curr. Treat. Options Neurol."},{"key":"10.1016\/j.neuropharm.2012.04.016_bib26","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/0165-6147(91)90630-B","article-title":"Mode of action of the anti-migraine drug sumatriptan","volume":"12","author":"Humphrey","year":"1991","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2012.04.016_bib27","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.tips.2008.10.004","article-title":"Regulation of neuronal T-type calcium channels","volume":"30","author":"Iftinca","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2012.04.016_bib28","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ceca.2006.04.024","article-title":"The role of peripheral T-type calcium channels in pain transmission","volume":"40","author":"Jevtovic-Todorovic","year":"2006","journal-title":"Cell Calcium"},{"key":"10.1016\/j.neuropharm.2012.04.016_bib29","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1098\/rspb.1965.0017","article-title":"The effect of calcium on acetylcholine release from motor nerve terminals","volume":"161","author":"Katz","year":"1965","journal-title":"Proc. R. Soc. Lond. B Biol. Sci."},{"key":"10.1016\/j.neuropharm.2012.04.016_bib30","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/j.1526-4610.2010.01669.x","article-title":"The lack of peripheral pathology in migraine headache","volume":"50","author":"Lambert","year":"2010","journal-title":"Headache"},{"key":"10.1016\/j.neuropharm.2012.04.016_bib31","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1046\/j.1468-2982.2002.00310.x","article-title":"CGRP may play a causative role in migraine","volume":"22","author":"Lassen","year":"2002","journal-title":"Cephalalgia"},{"key":"10.1016\/j.neuropharm.2012.04.016_bib32","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1073\/pnas.0306147101","article-title":"Disruption of communication between peripheral and central trigeminovascular neurons mediates the antimigraine action of 5HT 1B\/1D receptor agonists","volume":"101","author":"Levy","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.neuropharm.2012.04.016_bib33","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0304-3959(00)00475-9","article-title":"An in\u00a0vivo rat model to study calcitonin gene related peptide release following activation of the trigeminal vascular system","volume":"92","author":"Limmroth","year":"2001","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2012.04.016_bib34","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1046\/j.1468-2982.1997.1708833.x","article-title":"Differential distribution of 5HT1D- and 5HT1B-immunoreactivity within the human trigemino-cerebrovascular system: implications for the discovery of new antimigraine drugs","volume":"17","author":"Longmore","year":"1997","journal-title":"Cephalalgia"},{"key":"10.1016\/j.neuropharm.2012.04.016_bib35","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s00210-008-0322-7","article-title":"Current and prospective pharmacological targets in relation to antimigraine action","volume":"378","author":"Mehrotra","year":"2008","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.neuropharm.2012.04.016_bib36","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/BF00188214","article-title":"Innervation of the dura mater encephali of cat and rat: ultrastructure and calcitonin gene-related peptide-like and substance P-like immunoreactivity","volume":"188","author":"Messlinger","year":"1993","journal-title":"Anat. Embryol. (Berl.)"},{"key":"10.1016\/j.neuropharm.2012.04.016_bib37","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00221-009-1756-y","article-title":"Migraine: where and how does the pain originate?","volume":"196","author":"Messlinger","year":"2009","journal-title":"Exp. Brain Res."},{"key":"10.1016\/j.neuropharm.2012.04.016_bib38","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1146\/annurev.me.44.020193.001045","article-title":"SUMATRIPTAN: a receptor-targeted treatment for migraine","volume":"44","author":"Moskowitz","year":"1993","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.neuropharm.2012.04.016_bib39","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S1474-4422(09)70090-0","article-title":"Origin of pain in migraine: evidence for peripheral sensitisation","volume":"8","author":"Olesen","year":"2009","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2012.04.016_bib40","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/nrn1102","article-title":"Neurobiology of migraine","volume":"4","author":"Pietrobon","year":"2003","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2012.04.016_bib41","doi-asserted-by":"crossref","first-page":"10988","DOI":"10.1523\/JNEUROSCI.23-34-10988.2003","article-title":"Peptidergic nociceptors of both trigeminal and dorsal root ganglia express serotonin 1D receptors: implications for the selective antimigraine action of triptans","volume":"23","author":"Potrebic","year":"2003","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2012.04.016_bib42","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1468-2982.2005.01016.x","article-title":"Clinical-biochemical correlates of migraine attacks in rizatriptan responders and non-responders","volume":"26","author":"Sarchielli","year":"2006","journal-title":"Cephalalgia"},{"key":"10.1016\/j.neuropharm.2012.04.016_bib43","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.conb.2005.05.006","article-title":"Presynaptic calcium and control of vesicle fusion","volume":"15","author":"Schneggenburger","year":"2005","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.neuropharm.2012.04.016_bib44","doi-asserted-by":"crossref","first-page":"7174","DOI":"10.1523\/JNEUROSCI.20-19-07174.2000","article-title":"Low-affinity blockade of neuronal N-type Ca channels by the spider toxin omega-agatoxin-IVA","volume":"20","author":"Sidach","year":"2000","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2012.04.016_bib45","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1602\/neurorx.2.4.662","article-title":"Targeting chronic and neuropathic pain: the N-type calcium channel comes of age","volume":"2","author":"Snutch","year":"2005","journal-title":"NeuroRx"},{"key":"10.1016\/j.neuropharm.2012.04.016_bib46","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1741-7015-7-71","article-title":"Migraine pathogenesis and state of pharmacological treatment options","volume":"7","author":"Sprenger","year":"2009","journal-title":"BMC Med."},{"key":"10.1016\/j.neuropharm.2012.04.016_bib47","first-page":"1013","article-title":"Suppressing effect of the serotonin 5HT1B\/D receptor agonist rizatriptan on calcitonin gene-related peptide (CGRP) concentration in migraine attacks","volume":"37","author":"Stepien","year":"2003","journal-title":"Neurol. Neurochir. Pol."},{"key":"10.1016\/j.neuropharm.2012.04.016_bib48","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/cne.20106","article-title":"Axon diameters and intradural trajectories of the dural innervation in the rat","volume":"473","author":"Strassman","year":"2004","journal-title":"J.\u00a0Comp. Neurol."},{"key":"10.1016\/j.neuropharm.2012.04.016_bib49","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/j.1526-4610.2011.01892.x","article-title":"One hundred years of migraine research: major clinical and scientific observations from 1910 to 2010","volume":"51","author":"Tfelt-Hansen","year":"2011","journal-title":"Headache"},{"key":"10.1016\/j.neuropharm.2012.04.016_bib50","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.2165\/00003495-200060060-00003","article-title":"Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy","volume":"60","author":"Tfelt-Hansen","year":"2000","journal-title":"Drugs"},{"key":"10.1016\/j.neuropharm.2012.04.016_bib51","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s10194-009-0170-y","article-title":"Does sumatriptan cross the blood\u2013brain barrier in animals and man?","volume":"11","author":"Tfelt-Hansen","year":"2010","journal-title":"J.\u00a0Headache Pain"},{"key":"10.1016\/j.neuropharm.2012.04.016_bib52","doi-asserted-by":"crossref","first-page":"639","DOI":"10.2174\/187152706779025490","article-title":"The role of T-type calcium channels in peripheral and central pain processing","volume":"5","author":"Todorovic","year":"2006","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.neuropharm.2012.04.016_bib53","doi-asserted-by":"crossref","first-page":"238","DOI":"10.4161\/chan.4953","article-title":"Regulation of T-type calcium channels in the peripheral pain pathway","volume":"1","author":"Todorovic","year":"2007","journal-title":"Channels (Austin)"},{"key":"10.1016\/j.neuropharm.2012.04.016_bib54","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/j.1476-5381.2011.01256.x","article-title":"T-type voltage-gated calcium channels as targets for the development of novel pain therapies","volume":"163","author":"Todorovic","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2012.04.016_bib55","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/ana.20605","article-title":"No increase of calcitonin gene-related peptide in jugular blood during migraine","volume":"58","author":"Tvedskov","year":"2005","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2012.04.016_bib56","doi-asserted-by":"crossref","first-page":"219","DOI":"10.4161\/chan.3.4.9255","article-title":"Regulation of N-type calcium channels by G-proteins: multiple pathways to control calcium entry into neurons","volume":"3","author":"Weiss","year":"2009","journal-title":"Channels (Austin)"},{"key":"10.1016\/j.neuropharm.2012.04.016_bib57","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.brainresrev.2008.12.021","article-title":"Role of voltage-gated calcium channels in ascending pain pathways","volume":"60","author":"Zamponi","year":"2009","journal-title":"Brain Res. Rev."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390812001529?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390812001529?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,27]],"date-time":"2019-06-27T19:14:27Z","timestamp":1561662867000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390812001529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":57,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S0028390812001529"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2012.04.016","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}